Pipeline & Products
We specialize in injectables 505(b)(2) development.
Commercialized Products
You know the product name and our partners' names, but don’t know OUR name
Validation of Development Strategy
We have successfully developed and commercialized a range of innovative sterile injectable products to address unmet medical needs across multiple therapeutic areas.
- 9 novel 505(b)(2) Sterile Injectables products
- Internally conceived, patent-protected, and divested to a leading pharmaceutical company.
- Two of these products are on the market.
Our Pipeline
Products Under Development
Our advancing pipeline reflects a strong commitment to innovation and strategic partnerships.
- 6 injectable products in development
Designed to meet emerging clinical needs in hospitals and outpatient settings. - 3 partnered with a leading injectable pharmaceutical company
Further validating the scientific and commercial value of our pipeline.
Harshil – Formulation Scientist
Strong Patent Portfolio
Our intellectual property estate forms the foundation of our innovation and competitive advantage. We have:
- 32 granted patents – Covering key formulations, manufacturing processes and delivery methods.
- 14 pending patent applications – Ensuring the continued protection and expansion of our pipeline and platform assets.
Case Study
A Case Study: Revolutionizing Critical Care with RTU Norepinephrine
Nevakar Pharmaceuticals has transformed ICU efficiency and safety with its FDA-approved, ready-to-use (RTU), room temperature stable norepinephrine injection.
Key Strengths:
- Innovation-Driven: First-of-its-kind antioxidant-free, pH-optimized formulation in light-protected, oxygen-free IV bags—available in standard ASHP-recommended concentrations.
- Operational Excellence: 24-month shelf life, no refrigeration or compounding needed, reducing errors and enabling rapid emergency response.
- Supply Chain Resilience: Mitigates risk from IV fluid shortages by eliminating bedside dilution.
- IP Leadership: Backed by seven Orange Book-listed patents for formulation, packaging, and manufacturing.
- Platform Versatility: Core technology extended to other catecholamines, demonstrating a repeatable innovation model.
- Regulatory Milestone: Approved under the FDA 505(b)(2) pathway, accelerating time to market and de-risking development..